Crystallization of IGF-1
First Claim
Patent Images
1. A composition comprising human insulin-like growth factor-1 (IGF-1) of SEQ ID NO:
- 1 and N,N-bis(3-D-gluconamidopropyl)-deoxycholamine in a liquid solution.
0 Assignments
0 Petitions
Accused Products
Abstract
Crystalline IGF-1 is provided along with a method for production thereof. Crystallizing IGF-1 comprises the steps of mixing an aqueous solution comprising IGF-1 with a reservoir solution comprising a precipitant to form a mixture; and crystallizing the mixture, optionally also recrystallizing and isolating the crystalline IGF-1. In addition, a method for identifying IGF-1 indirect agonists is provided using a detergent as a standard for the level of inhibition of binding of IGFBP-1 or IGFBP-3 to IGF-1 and/or using the coordinates of the binding pockets of IGF-1 to which a candidate indirect agonist binds for structure-based drug design.
34 Citations
1 Claim
-
1. A composition comprising human insulin-like growth factor-1 (IGF-1) of SEQ ID NO:
- 1 and N,N-bis(3-D-gluconamidopropyl)-deoxycholamine in a liquid solution.
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeGenentech, Inc. (Roche Holding AG)
-
Original AssigneeGenentech, Inc. (Roche Holding AG)
-
InventorsUltsch, Mark, Schaffer, Michelle, Vajdos, Felix
-
Primary Examiner(s)Nashed; Nashaat T.
-
Application NumberUS11/471,912Publication NumberTime in Patent Office518 DaysField of SearchNoneUS Class Current530/324CPC Class CodesA61P 13/12 of the kidneysA61P 25/00 Drugs for disorders of the ...A61P 3/04 Anorexiants; Antiobesity ag...A61P 3/10 for hyperglycaemia, e.g. an...A61P 31/18 for HIVA61P 37/02 ImmunomodulatorsA61P 43/00 Drugs for specific purposes...A61P 9/00 Drugs for disorders of the ...C07K 14/65 Insulin-like growth factors...C07K 2299/00 Coordinates from 3D structu...
